Frequently Asked Questions
The At-Home Testing Kits Market size will be worth USD 11.95 billion by 2031 during the forecast period.
The At-Home Testing Kits Market growth rate is 6.1% during the forecast period.
The Testing Easy Availability of Self-Testing Kits at Pharmacies and Growing Adoption of Self-Testing Kits are the growth drivers of the At-Home Testing Kits Market.
The test type, type, age, sample type, usage, and distribution channels are the factors on which the At-Home Testing Kits Market research is based.
The major companies in the At-Home Testing Kits Market are Abbott (U.S.), Siemens Healthcare GmbH (Germany), F. Hoffmann-La Roche Ltd (Switzerland), BD (Becton, Dickinson and Company) (U.S.), Drägerwerk AG & Co. KGaA (Germany) , LifeScan IP Holdings, LLC (U.S.), Ascensia Diabetes Care Holdings AG (Switzerland), Nectar Lifesciences Ltd. (Rapikit) (India), ACON Laboratories, Inc. (U.S.), Quidel Corporation (U.S.), ARKRAY USA, Inc. (U.S.), BTNX INC. (Canada), Atomo Diagnostics (Australia), Eurofins Scientific (Luxembourg), Piramal Enterprises Ltd. (India), Bionime Corporation (Taiwan), Nova Biomedical (U.S.), Cardinal Health (U.S.), OraSure Technologies (U.S.), Biolytical Laboratories Inc. (Canada), Everlywell, Inc. (U.S.), SA Scientific Ltd. (U.S.), Clearblue (a subsidiary of Swiss Precision Diagnostics GmbH) (U.K.), Biosynex (France), PRIMA Lab SA (Switzerland), MP BIOMEDICALS (U.S.), Sterilab Services (France), Chembio Diagnostics, Inc. (U.S.), BioSure (U.K.), Selfdiagnostics OU (Estonia).
